ICAV is developing “wide-spectrum” anti-viral drugs that will target a variety of viral diseases while avoiding the emergence of resistant viruses. The ICAV scientific platform fundamentally changes the playing field by deploying a novel array of innovative blocking strategies that target human cell functions essential to viral infection.
Because of their rapid mutation rate, many viruses are able to develop resistance to conventional anti-virals that target the virus itself. The power of ICAV’s strategy lies in the fact that human functions do not mutate. Furthermore, as many viruses use the same set of human cellular functions to become infectious, drugs that inhibit these functions in the cell have the potential to work against a wide range of existing and newly emerging viruses.